Health

STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 02/11/2026, 21:06:25 UTC.

Briefings

Massachusetts biotech Kymera Therapeutics is preparing to announce clinical trial results for its lead eczema drug KT-621, positioning it to compete with the top-selling Dupixent. Analysts at Jefferies Bank predict KT-621 could generate nearly $4 billion in sales by 2035, with significant potential in eczema revenue. The announcement is expected to occur before the end of 2026.

Key points

• Kymera Therapeutics plans to announce clinical trial results for its lead eczema drug KT-621 before the end of 2026.
• Market analysts at Jefferies Bank forecast KT-621 sales could reach nearly $4 billion by 2035, with more than $3 billion in potential eczema revenue.

Context

Kymera Therapeutics is a Massachusetts-based biotech company developing KT-621 to treat eczema, asthma, and chronic spontaneous urticaria. The company faces intense competition from Sanofi and Regeneron's Dupixent, which has become the top-selling drug in immunology, generating tens of billions in revenue and transforming outcomes for 1.4 million patients. Success or failure of KT-621 could have major consequences for Kymera and the millions of people living with eczema in the United States.

Limitations

Evidence is limited to a single article from November 2026. The article does not provide specific dates for the trial results, exact patient numbers for KT-621, or the specific outcomes of the study. It also does not contain data on the trial's design, sample size, or statistical significance. The forecasted sales figures are based on analyst projections and are not confirmed facts.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/11/2026, 06:57:23 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeihlo75pfqoh2u47srbk5qtniotkjrfr2tl3do7ettkosi5bfk55zq